Fig. 7: Anti-MM activity of huCD26mAb in vivo. | Blood Cancer Journal

Fig. 7: Anti-MM activity of huCD26mAb in vivo.

From: CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma

Fig. 7

a The NOD/SCID model of MM. The NOD/SCID mice were subcutaneously inoculated with KMS18 cells that were co-cultured with OCs (5 × 106 cells per mouse). After 2 weeks, the tumors were established, and the mice were randomized into two groups. The mice (n = 5 × 2) were treated either PBS or huCD26mAb (10 mg/kg/dose) i.p. three times a week for 2 weeks. b Direct in vivo anti-tumor activity of huCD26mAb was compared with the control. Tumor specimens in PBS-treated versus huCD26mAb (10 mg/kg/dose)-treated MM-bearing NOD/SCID mice on study day 15 were shown. c The average tumor weights at necropsy in PBS-treated (control) versus huCD26mAb-treated mice were measured on study day 29. huCD26mAb significantly decreased the tumor weights compared with the control. The data are shown as the mean ± SD of three independent experiments. (*p < 0.05). d The NOD/SCID-hu model of MM. KMS18 cells cultured alone (5 × 106 cells per mouse) were directly injected into the human bone and subcutaneously implanted in the NOD/SCID mice. 4 weeks after tumor injection, when BM engraftment was confirmed, the mice were randomized into two groups. The mice (n = 5 × 2) were then treated with either PBS or huCD26mAb (10 mg/kg/dose) i.p. three times per week for 4 weeks. e huCD26mAb inhibits both CD26+ MM tumor burden and OC formation in vivo. Histology and immunohistochemical findings from the collected human bones were shown (from the left panel: H&E, ×100, ×200; CD26 stain, ×200; TRAP stain, ×200). Continuous treatment with huCD26mAb significantly inhibited CD26+ MM cell growth. In addition, a number of TRAP+ OCs were observed in the control mice, whereas huCD26mAb markedly decreased the number of TRAP+ OCs in human bones of the huCD26mAb-treated mice. huCD26mAb inhibits both MM tumor burden and OC formation in vivo. f The number of TRAP+ OCs in the human bones was quantified under three random fields at ×100 magnification. The number of OCs was significantly lower in huCD26mAb-treated mice than in the control mice (*p < 0.05)

Back to article page